Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2017-05-31 Regulatory Filings
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Rejestracja leku Salmex na rynku w Kazachstanie - Content (PL)
Regulatory Filings Classification · 90% confidence The document is a short announcement (1208 characters) from the Management Board ('Zarząd') of Celon Pharma S.A. It reports receiving information on May 31, 2017, regarding the registration of the drug Salmex (Salmerix) in Kazakhstan via a business partner. It discusses the implications for commercialization and export strategy, and briefly describes the drug's composition and indications (asthma, COPD). This is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is a specific operational update concerning market expansion and product registration, which does not fit neatly into the primary financial categories. Given the nature of the announcement—a specific, non-financial regulatory/operational event update—and its brevity, the most appropriate fallback category is Regulatory Filings (RNS), as it is a general regulatory announcement that doesn't match the more specific operational/financial codes.
2017-05-31 Polish
Zawarcie przez GLG Pharma LLC umowy o współpracy z Trigon TFI. - Content (PL)
Regulatory Filings Classification · 95% confidence The document text, written in Polish, describes an agreement ('Umowa') reached between GLG Pharma S.A., GLG Pharma LLC, and Trigon TFI S.A. The core of the agreement involves Trigon TFI S.A. gaining the right to nominate a candidate for the Supervisory Board ('Rady Nadzorczej') of GLG Pharma S.A., and guarantees Trigon's participation in future share offerings. This concerns changes in corporate governance, board structure, and potential future financing/share activity. Since the document details a specific agreement impacting board composition and future capital involvement, it relates most closely to corporate governance or potential financing/share activity. Given the specific focus on board nomination rights and future participation in offerings, it is not a standard M&A takeover (TAR), nor a simple management change (MANG). It is a specific agreement detailing corporate control/governance aspects. However, none of the definitions perfectly capture a strategic cooperation agreement focused on board representation and future capital rights. It is not an ER, IR, or 10-K. It is not a Director's Dealing (DIRS). It is a significant corporate action/agreement. Given the options, 'Capital/Financing Update' (CAP) is plausible due to the mention of future share offers, but the primary action is governance-related (board seat). 'Governance Information' (CGR) covers internal rules and board structure. Since this agreement directly dictates board composition and future capital rights, CGR is the most appropriate fit among the provided specific codes for a document detailing structural agreements.
2017-05-31 Polish
Raport Kwartalny Celon Pharma
Interim / Quarterly Report Classification · 100% confidence The document is a 'Raport Kwartalny' (Quarterly Report) for Celon Pharma S.A. for the first quarter of 2017. It contains detailed financial statements, including a balance sheet (Bilans), income statement (Rachunek zysków i strat), and cash flow statement, as well as extensive notes and management commentary. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2017
2017-05-26 Polish
Raport Kwartalny Celon Pharma
Interim / Quarterly Report Classification · 100% confidence The document is a 'Raport Kwartalny' (Quarterly Report) for Celon Pharma S.A. for the first quarter of 2017. It contains detailed financial statements, including a balance sheet (Bilans), income statement (Rachunek zysków i strat), and cash flow statement, as well as extensive notes and management commentary. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2017
2017-05-26 Polish
Wykaz akcjonariuszy dysponujących co najmniej 5% głosów na Zwyczajnym Walnym Zgromadzeniu Spółki w dniu 25 maja 2017 r. - Content (PL)
AGM Information Classification · 99% confidence The document text is very short (503 characters) and appears to be a regulatory disclosure in Polish, referencing Article 70, point 3 of the Public Offering Act ('Ustawa o ofercie publicznej'). It specifically details the voting results and major shareholder (Glatton Sp. z o.o. holding 75% of votes) at an Extraordinary General Meeting ('Zwyczajnym Walnym Zgromadzeniu') held on May 25, 2017. This content directly relates to the official results of a shareholder vote. Therefore, the most appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2017-05-26 Polish
Uchwały ZWZ
AGM Information Classification · 100% confidence The document text is titled "UCHWAŁY PODJĘTE PRZEZ ZWYCZAJNE WALNE ZGROMADZENIE" (Resolutions adopted by the Annual General Meeting) and details numerous resolutions (Uchwała nr 1 through 15) passed on May 25, 2017. These resolutions cover the election of the Chairman, approval of the agenda, approval of the 2016 Annual Report and Financial Statements, profit distribution (including dividend), and crucially, the granting of 'absolutorium' (vote of confidence/discharge) to members of the Management Board and Supervisory Board for the 2016 fiscal year. The content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2017-05-25 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.